Review
Role of 11β-hydroxysteroid dehydrogenase 1 in metabolic diseases: the latest progress
Pan Qiyu, Han Tingting, Li Guoping
Published 2021-08-14
Cite as Chin J Geriatr, 2021, 40(8): 1069-1074. DOI: 10.3760/cma.j.issn.0254-9026.2021.08.028
Abstract
The 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1)is the only enzyme in the body, which can convert inactive cortisone(11-dehydrocorticosterone in rodents)to active cortisol(corticosterone in rodents)in vivo.And it is vital for regulating the level of active glucocorticoids in local tissues.It has been implicated that glucocorticoid dysregulations are closely related to various metabolic diseases, such as obesity and type 2 diabetes mellitus(T2DM), etc.Therefore 11β-HSD1 may be a potential target for the treatment of metabolic diseases.In this review, we summarize the biological function and tissue distribution of 11β-HSD1, discuss how 11β-HSD1 participates in physiological and pathological mechanisms of obesity, T2DM, non-alcoholic fatty liver disease, hypertension and sarcopenia, and sum up the advanced developments of 11β-HSD1 inhibitors.
Key words:
11β-Hydroxysteroid dehydrogenase type 1; Glucocorticoids; Obesity, morbid; Diabetes Mellitus Type 2; Fatty liver
Contributor Information
Pan Qiyu
The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission
Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Han Tingting
The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission
Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Li Guoping
The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission
Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China